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MS EDSS state, convert from RRMS to SPMS or die. Patients have a fixed annual
probability of relapse and death. RRMS patients with EDSS score 7 were eligible
for disease modifying therapies (DMTs). Patients with SPMS or EDSS score 7 re-
ceived best supportive care. Transition probabilities were based on natural history
of RRMS. Efficacy (i.e. on relapse rates and disability progression) was obtained
from a mixed treatment comparison of published results. Health utilities were
obtained from Orme et al (2007). Resources use (physician consultations; ambula-
tory care; hospitalization, other drugs, services, DMT monitoring and administra-
tion) were validated by an experts’ panel and valued using Brazilian official lists.
Annual discount rate of 5% was applied both to costs and outcomes. Probabilistic
sensitivity analysis (PSA) was performed. RESULTS:Adopting WHO threshold, base
case analysis showed fingolimod is more effective and less costly (dominant) ver-
sus IFN--1a 44mcg (incremental costs: -26,567BRL; QALY: 0.223) and cost-effec-
tiveness versus IFN--1a 30mcg; IFN--1a 22mcg and IFN--1b 300mcg, with ICER
(BRL/QALY): 29,306; 6,725 and 52,626, respectively (3 GDP/capita or BRL 57,000.00;
1USD  2.055BRL). PSA has confirmed the consistency of base case results.
CONCLUSIONS: In the treatment of patients with RRMS, fingolimod provides su-
perior effectiveness and represents good value for money in comparison with the
most common first line therapies by the health care payer in Brazil.
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OBJECTIVES: Despite the use of anti-epileptics, approximately 20-30 % of epileptic
patients in Spain experience recurrent convulsive seizures, which require rescue
medication and, sometimes, hospitalisation. Current standard first-line treatment
of prolonged, acute, convulsive seizures (PACS) in the community setting com-
prises rectal diazepam (RD). Buccolam (licensed oromucosal midazolam) is the
only oral paediatric formulation approved for the treatment of PACS in children (3
months to18 years). We assessed the cost effectiveness of Buccolam compared to
RD in the community setting in Spain. METHODS: A decision-tree model was de-
veloped to capture quality-of-life and cost implications of PACS. We assessed the
treatment pathway when a child has a seizure in the community including
whether or not carers administer treatment; an ambulance is required; patients are
taken to hospital and require an inpatient stay. The associated cost and health-
related quality of life (HRQL) impacts were calculated. Data were obtained from
many sources including clinical-effectiveness estimates from McIntyre et al. 2005,
a Delphi panel and a survey of parents to ascertain current practice. Costs were
taken from published sources. Sensitivity analyses were conducted on both sets of
data. RESULTS: Over one year, Buccolam showed a cost reduction of €4,994 per
patient compared to RD and HRQL improvement of 0.0075 QALYs. The price of
Buccolam would need to be more than €463/patient/year to not be cost saving.
Buccolam remained dominant across a range of scenario analyses. Reduction in
hospitalisations was the primary reason for overall cost savings (67% from reduced
ward costs, 10% from reduced ICU costs). Ambulance and emergency costs were
also significantly reduced (23% of total savings). CONCLUSIONS: Treatment with
Buccolam is cost saving compared to rectal diazepam through a reduction in hos-
pitalisations and ambulance call-outs.
PND42
COST-EFFECTIVENESS OF ONABOTULINUMTOXIN-A FOR THE PROPHYLAXIS OF
CHRONIC MIGRAINE
Ruggeri M1, Carletto A2, Marchetti M3
1Università Cattolica del Sacro Cuore, rome, Italy, 2Università Cattolica del Sacro Cuore, Rome,
Italy, 3University Hospital, Rome, Italy
OBJECTIVES: To determine the cost-effectiveness of onabotulinumtoxinA versus
placebo in patients with chronic migraine from the Italian National Health Service
and a societal perspective.METHODS: The economic analysis is based on a Markov
Model developed to evaluate costs and effects for a cohort of patients treated with
onabotulinumtoxinA or placebo over a 2 year timeframe. The model is based on six
health states (headache present on 0-3; 4-9; 10-14; 15-19; 20-23; 24-28 days/month)
and combines data from published clinical trials (PREEMPT pooled data) with direct
and indirect costs. Costs considered included medications, treatment administra-
tion, hospitalizations, GP visits, emergency room visits and loss of productivity.
Costs and effects were both discounted at 3% per year. Univariate and multivariate
probabilistic sensitivity analysis using 10,000 Monte Carlo simulations were con-
ducted to test the robustness of results. RESULTS: In the case-base model, on-
abotulinumtoxinA was associated with an incremental number of QALYs of 0,04
per patient; the expected incremental cost per patient was € 208; the expected
incremental cost per QALY gained was therefore € 2.824. The strategy of chronic
migraine treatment with onabotulinumtoxinA is dominant as compared to placebo
if the perspective of society is adopted. Results are slightly sensitive to the utility
values used for both onabotulinumtoxinA and placebo. Multivariate sensitivity
analysis showed that there is a 69% chance that onabotulinumtoxinA is cost-effec-
tive if society is willing to pay € 30.000/QALY and 68% at a willingness to pay
threshold of € 20.000/QALY. CONCLUSIONS: This study suggests that Onabotuli-
numtoxinA improve clinical outcomes at a reasonable cost, and may actually be
cost-saving when compared to placebo if the societal perspective is adopted. Its
additional costs are offset by savings associated with a decrease in resource use
and an increase in productivity.
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OBJECTIVES: To assess the cost-utility analysis of intraosseous blockades vs con-
servative treated of patients with low back pain over 12 months.METHODS:A total
of 62 patients between 22 and 73 years old with a diagnosis of low back pain. Low
back pain patients were randomized of two group. Patients of the first (main) group
received a course of intraosseous blockades (Sokov EL, 1996), while patients of the
second (control group) received a course of conservatively treatment (analgetics,
NSAIDs, myorelaxants, physical therapy). Measured direct costs at 1-year follow-
up. Quality of life was measured with the Oswestry low back pain disability ques-
tionnaire, converted into utilities and transformed into quality-adjusted life years
- QALY. The analysis will be performed for the health systems. Costs were mea-
sured in EUR. RESULTS:Quality of life improved significantly at 1-year follow-up in
first group. Mean QALY in the first group was 0.358 and 0.105 in the second group.
The medical costs were much lower for intraosseous blockades treatment. The
cost-utility ratio for first group was 705,7 EUR for 1 QALY, and for standard therapy
it was 3701,5 EUR for 1 QALY. The difference in QALY’s gained during 1 year be-
tween both the groups was in fivefold in favor of the first group – 2995,8 EUR.
CONCLUSIONS: Use of intraosseous blockades compared with conservatively
treated offer significant long-term benefits in quality of life. The total costs for
intraosseous blockades were lower due to lower a reduction in the duration of
episodes the low back pain than conservatively treatments. Lower total costs and
better utility resulted in a better cost-utility for intraosseous blockades treatment.
Our analysis have demonstrated the cost-utility of intraosseous blockades.
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OBJECTIVES: To determine cost-utility of Sabril®in the treatment of drug-resistant
epilepsy compared to lamotrigine, gabapentin, topiramate, tiagabine, oxcarbaz-
epine or levetiracetam in Polish conditions.METHODS: In order to determine long-
term costs and health effects of interventions, a Markov model was built and it
assumed two-step treatment of epileptics. The Cost Effectiveness Analysis Registry
Database was searched to find health state utilities. Costs in the analysis were
presented from Polish payer’s perspective, in lifetime horizon which was divided
into 3-month cycles. Only direct medical costs regarding 1st and 2nd line drug
costs, diagnostic costs, ambulatory and hospital treatment were taken into ac-
count. Costs and health effects were discounted at 5% and 3.5% rate, respectively.
A cost-utility analysis was conducted for comparison with gabapentin and lam-
otrigine while a cost-minimisation analysis was an analytical technique for com-
parisons with topiramate, tiagabine, oxcarbazepine and levetiracetam. Cost of ad-
verse events after vigabatrin administration was not taken into consideration due
to heterogenous information about risk of adverse events. RESULTS: Epilepsy ther-
apy with vigabatrin brought 0.0172QALYG comparing to gabapentin however it was
more expensive by 1526.75PLN. The administration of lamotrigine was less costly
in reference to vigabatrin (by 532.45PLN) and health effects of treatment with lam-
otrigine were superior (by 0.0091QALY). Incremental costs of vigabatrin adminis-
tration were positive in comparison to topiramate and tiagabine (3637PLN and
1831PLN) and negative in reference to oxcarbazepine and levetiracetam (-1461PLN
and -2942PLN). CONCLUSIONS: The administration of vigabatrin in drug-resistant
epilepsy was cost-effective in comparison to gabapentin however it was dominated
by treatment with lamotrigine. Epilepsy therapy with vigabatrin was more expen-
sive than treatment with topiramate or tiagabine while it was less expensive treat-
ment option than the administration of oxcarbazepine and levetiracetam.
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OBJECTIVES: To examine use of donepezil 23 (D23) in a real-world setting among
medicare and commercially insured patients. METHODS: Patients diagnosed with
Alzheimer’s disease (ICD-9-CM 331.xx),  50 years old initiating D23 (index date)
during 7/1/2010-5/31/2011 with 3 months pre- and 6 months post-index eligibility
were identified from Humana claims database (medicare 60%, commercial 40%).
Demographic characteristics were measured pre-index. Clinical characteristics
were measured pre- and post-index. Patients were categorized into 2 cohorts: con-
tinued (CON), discontinued (DIS). Discontinuation was defined as a gap of 30 days
post-index. Outcomes assessed: time on 10 mg donepezil (pre-index), AD-related
health care resource utilization and costs, length of therapy and time to discontin-
uation and use of memantine. RESULTS:A total of 479 patients were identified: 204
CON, 275 DIS. Mean age [SD] was less for CON (78.8 [7.5] v 80.5 [7.3]; p0.012) with
no differences in comorbidity scores (0.37). 59.3% of CON patients, and 67.3% of DIS
patients were female (p0.073). Over half used memantine, with greater percent-
age of CON patients using memantine compared to DIS patients pre-(68.1% v 52.0%;
p0.0004) and post-index (77.0% v 58.9%; p0.0001). More CON patients had  60
days of pre-index 10 mg donepezil use (62.2% v 45.4%; p0.0003). More DIS patients
had an ER visit (10.2% v 3.9%; p0.035) compared to CON patients. Length of stay in
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